{"id":3895,"date":"2022-09-04T05:33:21","date_gmt":"2022-09-04T05:33:21","guid":{"rendered":"https:\/\/modafinil.pl\/?post_type=product&p=3895"},"modified":"2026-10-03T05:28:10","modified_gmt":"2026-10-03T05:28:10","slug":"bromantane","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/bromantane\/","title":{"rendered":"Bromantane (ADK-709) \u2014 Chemical Reagent 1000 mg, Purity \u2265 99.75%, CAS 87913-26-6"},"content":{"rendered":"

N-(4-bromophenyl)adamantan-2-amine<\/strong>, purity ≥ 99.75%, 1000 mg package. Material intended exclusively for in vitro laboratory and analytical research<\/strong>. The product is not intended for consumption by humans or animals<\/strong>, is not a medicinal product, dietary supplement, foodstuff, or cosmetic.<\/p>\n

Reagent Identification Card<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registration data and identifiers — bromantane<\/caption>\n
Systematic name (IUPAC)<\/th>\nN-(4-bromophenyl)adamantan-2-amine<\/td>\n<\/tr>\n
Common name<\/th>\nbromantane (bromantan, bromontan)<\/td>\n<\/tr>\n
Development code<\/th>\nADK-709<\/td>\n<\/tr>\n
CAS number<\/th>\n87913-26-6<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC16<\/sub>H20<\/sub>BrN<\/td>\n<\/tr>\n
Molar mass<\/th>\n306.24 g·mol−1<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n305.0779 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nLWJALJDRFBXHKX-UHFFFAOYSA-N<\/td>\n<\/tr>\n
SMILES<\/th>\nC1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br<\/td>\n<\/tr>\n
PubChem CID<\/th>\n4660557<\/td>\n<\/tr>\n
UNII (FDA)<\/th>\nN1ILS53XWK<\/td>\n<\/tr>\n
ChEMBL<\/th>\nCHEMBL4303520<\/td>\n<\/tr>\n
MDL number<\/th>\nMFCD02101627<\/td>\n<\/tr>\n
Form<\/th>\ncrystalline powder, white to off-white<\/td>\n<\/tr>\n
Purity<\/th>\n≥ 99.75%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent — not for consumption by humans or animals<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Three Distinct Entities That Must Not Be Confused<\/h2>\n

With this molecule, confusion is especially easy, which is why we separate the layers from the outset. The same chemical name occurs in three entirely different contexts, with different legal status, different quality control, and different intended use:<\/p>\n\n\n\n\n\n
Timeline: Origin and Spread of the Molecule<\/caption>\n
Chemical substance<\/strong>
bromantane, CAS 87913-26-6<\/td>\n		A chemical concept — a defined molecule with a defined structure. On its own it is neither a drug nor a reagent; its status is conferred only by the form in which it was manufactured and approved.<\/td>\n<\/tr>\n
Medicinal product<\/strong>
Ladasten, registered in the Russian Federation (2009)<\/td>\n		A pharmaceutical preparation: a defined pharmaceutical form, manufacture under pharmaceutical conditions, registration documentation, safety surveillance. It is this entity that the human clinical studies<\/strong> cited in the literature [14][20] concerned.<\/td>\n<\/tr>\n
Chemical reagent<\/strong>
the material offered on this page<\/td>\n		A material for laboratory and analytical work. It does not and cannot have approval for use in humans or animals<\/strong>: it has no pharmaceutical form, is not subject to pharmaceutical manufacturing conditions, and is not accompanied by medicinal product documentation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous and not open to interpretation.<\/strong> The study results cited later on this page were obtained either using the registered medicinal product<\/strong> (human clinical studies), or using the substance administered to laboratory animals under controlled experimental conditions<\/strong> (preclinical studies). None of these studies were conducted using the analytical reagent<\/strong>, and none of these results transfer to the material offered here. The reagent is not the form in which the substance was ever studied in humans, and it cannot be used in that way.<\/p>\n

We cite the literature because a reliable description of a laboratory material requires indicating where the knowledge about the molecule came from and where to find it. This is not information about the product’s effects, does not constitute encouragement for any use outside the laboratory, and cannot be the basis for any health-related decision.<\/strong><\/p>\n

Lineage of the Molecule: Where the Adamantane Cage Came From<\/h2>\n

Bromantane cannot meaningfully be described in isolation from the family it belongs to. The core of the molecule is adamantane<\/strong> — a cage-structured hydrocarbon whose skeleton corresponds to the elementary unit cell of diamond. This compound was isolated from a petroleum fraction in the 1930s, and for the following two decades it remained a laboratory curiosity, since no efficient route to its production existed. The situation changed only with a synthesis developed in the late 1950s using a Lewis-acid-catalyzed rearrangement, which lowered the cost of the material enough that the adamantane cage became an accessible building block for medicinal chemistry.<\/p>\n

The consequences were far-reaching. The rigid, strongly lipophilic cage proved to be a convenient structural handle: attaching an amino group to it gave the aminoadamantane derivatives<\/strong>, the best known of which is amantadine. It is this line of research — and not, as is sometimes incorrectly stated, a chance discovery in a single year — that constitutes the real context for the emergence of bromantane.<\/p>\n

Bromantane belongs to the 2-aminoadamantanes<\/strong>, a subgroup in which the amino substituent is located at position 2 of the cage rather than at the bridgehead position 1. A 4-bromophenyl ring is attached to the nitrogen atom. This seemingly minor synthetic decision has two consequences relevant to the analytical laboratory: it increases the molecule’s lipophilicity (calculated XLogP ≈ 5) and introduces a bromine atom which, as discussed below, gives a characteristic signature in the mass spectrum.<\/p>\n

Timeline: How Knowledge of Bromantane Developed<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Computational Descriptors and Their Analytical Significance<\/caption>\n
1930s<\/th>\nisolation of adamantane from petroleum<\/td>\n<\/tr>\n
late 1950s<\/th>\nefficient synthesis of adamantane; the cage becomes an accessible building block<\/td>\n<\/tr>\n
1960s–1970s<\/th>\ndevelopment of aminoadamantane derivatives in medicinal chemistry<\/td>\n<\/tr>\n
1980s<\/th>\ndevelopment of the compound under the code ADK-709<\/strong> in the Soviet actoprotector research program<\/td>\n<\/tr>\n
first half of the 1990s<\/th>\nfirst indexed experimental papers; formation of three research centers<\/td>\n<\/tr>\n
1996<\/th>\ndetection of the substance in anti-doping control samples — the molecule’s international debut<\/td>\n<\/tr>\n
1997<\/th>\naddition to the list of substances banned in sport<\/td>\n<\/tr>\n
1999–2006<\/th>\na series of toxicological and behavioral studies in animals [1][2][3][4][5][6][7]<\/td>\n<\/tr>\n
2004–2005<\/th>\ngene expression studies using DNA macroarrays at the Ufa center [8][9][10]<\/td>\n<\/tr>\n
2009<\/th>\nregistration of the medicinal product<\/strong> under the trade name Ladasten in the Russian Federation (concerns the pharmaceutical preparation, not the reagent)<\/td>\n<\/tr>\n
2010–2013<\/th>\nclinical studies using the medicinal product<\/strong> and reviews of the actoprotector category [14][17][20]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Three Centers That Built the Literature<\/h2>\n

The literature on bromantane has an unusual geography: it originated almost entirely in three centers of the former USSR, in the Russian language, and a significant portion of it has never been replicated outside that region. For a laboratory using this reagent, this has practical implications — when verifying literature data, one encounters records indexed only by a translated title.<\/p>\n